AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
[{"orgOrder":0,"company":"MabGenesis","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Boehringer Ingelheim Collaborates with MabGenesis to Discover & Develop Novel Monoclonal Antibodies in Canine","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"JAPAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform"}]

Find Clinical Drug Pipeline Developments & Deals by MabGenesis

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Under the agreement, MabGenesis will apply its unique platform to the discovery of first-in-class candidate antibodies against targets of interest selected by Boehringer Ingelheim.

            Lead Product(s): Monoclonal Antibody

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 18, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY